Please login to the form below

Not currently logged in
Email:
Password:

Cancer Research

This page shows the latest Cancer Research news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda meets survival challenge in NSCLC

Merck’s Keytruda meets survival challenge in NSCLC

Merck &Co’s grip on the first-line non-small cell lung cancer (NSCLC) immunotherapy market seems set to tighten, after its PD-1 inhibitor Keytruda halved the risk of death ... The first look at data from the KEYNOTE-189 study, presented at the American

Latest news

More from news
Approximately 19 fully matching, plus 342 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    For the moment, the mood music is bright. Research into its lead compound Milciclib, a small molecule inhibitor of cyclin dependent kinases (CDKs), has just been published in the journal Cancer ... The first trial was with 16 cancer patients who were

  • Winning the war against cancer Winning the war against cancer

    I don't want to trivialise cancer, [but] from a pure research perspective, looking at performance of health systems, cancer is a very good tracer indicator of how health systems are ... Cancer is an important disease to see [its] impact on the health

  • Deal Watch January 2017 Deal Watch January 2017

    Using a similar structure, Takeda also announced a collaboration with possible future acquisition of Maverick which focuses on next-generation T-cell cancer research. ... Merck KGaA / Palantir. Combining Merck's research with other bioinformatics for

  • Challenging times Challenging times

    continents. We surveyed 21, 300 research participants with a range of chronic diseases including but not limited to high blood pressure, high cholesterol, diabetes, asthma, heart conditions and cancer. ... Two thirds of our research participants said

  • Deal Watch January 2016 Deal Watch January 2016

    Dual Therapeutics' small-molecule modulators are designed to simultaneously block multiple cancer-promoting pathways. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research collaboration; includes option to acquire the company.

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    At the time, lead investigator James Kochenderfer from the Center for Cancer Research at the National Cancer Institute in Bethesda said: “We have patients who have a sustained response and have ... and a $1.1bn agreement to acquire Impact Biomedicines

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... Association for Cancer Research.

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Additionally, Dr Jon Roffey joins Glythera ’s scientific advisory board (SAB) from

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    s cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    Workman currently serves The Institute of Cancer Researc h as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research ... world class cancer institute and being a founder of

More from appointments
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • Why is the UK lagging behind the rest of Europe in cancer survival?

    Why is the UK lagging behind the rest of Europe in cancer survival? ... Research on prostate, lung and bowel cancer tests are under way at the Royal Marsden and a similar blood test has already been  reported as a breakthrough for predicting relapses in

  • How did pharma use Twitter at #ASCO16?

    The meeting is one of the largest gatherings of medical professionals in the world, with world-renowned faculties discussing the very latest in cancer treatment, and ground-breaking research announced throughout ... on cancer prevention, treatments,

  • Alzheimer's: the numbers we cannot forget

    The number of deaths in AD per year is on par with  cancer, and the annual cost of care actually exceeds that of cancer - which is surprising considering there is  10x ... more research funding in cancer than AD.

  • Why is the UK lagging behind the rest of Europe in cancer survival?

    Why is the UK lagging behind the rest of Europe in cancer survival? ... Research on prostate, lung and bowel cancer tests are under way at the Royal Marsden and a similar blood test has already been  reported as a breakthrough for predicting relapses in

More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics